Trial Profile
A Single-blind, Multiple Dose, Placebo-controlled, Double Dummy Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Furosemide (Primary)
- Indications Essential hypertension; Heart failure
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 03 May 2012 Actual end date (August 2011) added as reported by ClinicalTrials.gov.
- 03 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Apr 2011 Lithuania added as study country